Analysis of prognostic factors and different treatment modalities for patients with early cervical squamous cell carcinoma after surgery in Xinjiang

Abstract

Objective To explore prognostic factors and different treatment modalities efficacy for patients with early cervical squamous cell carcinoma postoperative. Methods The clinical pathologic parameters in 130 inpatients of cervical squamous cell carcinoma after surgical were retrospectively analyzed. The patients were followed up for 5 years. The survival rate was calculated by Kaplan-Meier method and the difference was compared by Log-rank test. Multivariate analysis was performed using Cox regression model. Results Univariate analysis showed that parity(χ2=7.378, P=0.007), Federation International of Gynecology and Obstetrics (FIGO) stage (χ2=4.124, P=0.042), tumor size (χ2=4.070, P=0.044), lymph node metastasis (χ2=11.936, P=0.001), treatment approach (χ2=8.523, P=0.014), serum level of squamous cell carcinoma antigen (SCCA) (χ2=6.399, P=0.011)and platelet and lymphocyte ratio (PLR) (χ2=5.588, P=0.018) impact on the 5-year survival rate. Multivariate analysis showed that parity (OR=4.379, 95%CI: 1.492-12.854, χ2=7.226, P=0.007), FIGO stage (OR=4.129, 95%CI: 1.401-12.168, χ2=7.827, P=0.005), lymph node metastasis (OR=7.312, 95%CI: 2.617-20.430, χ2=14.819, P=0.000), treatment approach (OR=0.242, 95%CI: 0.082-0.713, χ2=6.662, P=0.010) and PLR (OR=5.375, 95%CI: 1.351-21.375, χ2=5.862, P=0.017) were independent prognostic factors for cervical squamous cell carcinoma patients. In 106 cases of patients with risk factors of cervical squamous cell carcinoma, patients who having surgery alone, surgery plus radiotherapy, surgery plus chemoradiotherapy had 5-year survival rates of 61.8%, 83.3% and 90.4%, respectively, and the difference was statistical significant (χ2=8.467, P=0.014). Conclusion Parity, FIGO stage, lymph node metastasis, treatment approach and PLR are independent prognostic factors in patients with early cervical squamous cell carcinoma. Adjuvant therapy is recommended in cervical cancer patients with risk factors after operation, it can improve patients′ survival rates and quality of life. Key words: Uterine cervical neoplasms; Prognosis